statine

Statine is a protease inhibitor that is active against pepsin and other acid proteases.

Renin inhibitory peptide, statine is a effective, specific statine-containing renin inhibitor.

Carnostatine (SAN9812) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. It may be used to increase renal carnosine concentration as a potential therapeutic modality for diabetic nephropathy (DN). [1].

Carnostatine hydrochloride (SAN9812 hydrochloride) is a potent and selective inhibitor of carnosinase 1 (CN1), with a K_i of 11 nM against human recombinant CN1, showing promise for the treatment of diabetic nephropathy (DN) [1].

Auristatin E, a cytotoxic tubulin modifier, disrupts cell division by inhibiting tubulin polymerisation. This compound demonstrates potent and selective antitumor activities, serving as an MMAE analog and cytotoxin in antibody-drug conjugates.

Atorvastatin Epoxy Tetrahydrofuran Impurity is an isolated oxidative degradation product of Atorvastatin, an orally active HMG-CoA reductase inhibitor.

Atorvastatin ethyl ester, a derivative of Atorvastatin, exhibits potent inhibition of 9-cis-RA-induced Gal4 reporter activity.

MMAE-D8 is a deuterated compound of MMAE (T6897-GMP) (Monomethyl Auristatin), suitable for isotope tracing. MMAE (T6897-GMP) is a tubulin microtubule inhibitor that suppresses cancer cell mitosis and is frequently employed in antibody-drug conjugate (ADC) development.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

MMAU (β-D-Glucuronylmonomethylauristatin E) is a payload that is relatively stable in its unbound free state. Lysosomal enzymes convert it to a deglycosylated state, which activates the cytotoxicity of the payload.

(4R,5S)-MonomethylauristatinE intermediate-6 is an intermediate reactant in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity and is widely utilized as the cytotoxic component in antibody-drug conjugates (ADC Cytotoxin).

MonomethylauristatinE intermediate-8 is an intermediate compound in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) acts as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

MonomethylauristatinE intermediate-10 is an intermediate used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs) [ADC Cytotoxin].

MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

Cilastatin (MK-0791) is a potent, reversible, competitive inhibitor of renal dehydropeptidase I (DHP-I), exhibiting an IC₅₀ of 0.1 μM. By inhibiting DHP-I in the kidney, Cilastatin prevents the enzymatic degradation of β-lactam antibiotics, thereby enhancing their stability and therapeutic efficacy. In addition, Cilastatin demonstrates inhibitory activity against the bacterial metallo-β-lactamase enzyme CphA, with an IC₅₀ of 178 μM. Clinically and experimentally, Cilastatin is widely used as an antibacterial adjunct to improve antibiotic performance and reduce renal metabolism of co-administered β-lactam drugs.

Alrestatin is a specific inhibitor of the aldose reductase enzyme.

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.

I 432 is a TMPRSS2 (transmembrane serine proteinase 2) inhibitor (Ki =0.9 nM).

Aminobenzenesulfonic auristatin E is a potent antitumor agent-linker conjugate for Antibody-Drug Conjugates (ADC). It utilizes Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker, Aminobenzenesulfonic [1], to exhibit significant antitumor activity.

Aminobenzenesulfonic Auristatin E TFA, an agent-linker conjugate for ADC, exhibits potent antitumor activity. It employs Auristatin E (a cytotoxic tubulin modifier) connected through the ADC linker Aminobenzenesulfonic [1].

Nonapeptide-1 (Melanostatine™ 5) can inhibit the synthesis of melanin, which makes it of interest for treating certain skin conditions.

Agistatin E, a pyranacetal derived from Fusarium species, impedes cholesterol biosynthesis [1].

Aminobenzenesulfonic auristatin E-D8 is a deuterated version of Aminobenzenesulfonic auristatin E (T74483), which forms part of an antibody-drug conjugate. This compound is synthesized by linking the cytotoxic microtubule modifier Auristatin E with the ADC linker Aminobenzenesulfonic, endowing it with antitumor activity.